The deal - financial terms of which were not disclosed - follows a long-standing collaboration and is designed to support the US contract research organisation's (CRO) expanding business according to chairman Boris Reznik
Reznik told Outsourcing-Pharma.com that bioRASI is growing approximately “40% to 50% a year,” adding that SCRG had worked “seamlessly” over the past eighteen months “as an extension of bioRASI, consistently exceeding our expectations, beating aggressive timelines and producing outstanding quality outcomes.”
He stressed that the acquisition is not about geographic expansion - bioRASI already has an established presence in Ukraine - but is instead designed to add depth to the firm's offering in the country.
“While bioRASI has had a presence in Ukraine for a decade, this acquisition represents a major expansion of our strength there,” Reznik said. Some of SCRG’s staff have been working under bioRASI’s proprietary Process Infrastructure (BPI) for 18 months and the rest of the staff will be integrated into bioRASI “by the end of this year,” Reznik told us.
Increasing Growth
“One challenge this rate of growth presents is to maintain the highest quality of personnel we pride ourselves on,” Reznik said. “So when an opportunity comes along to acquire a team of people who have proved themselves as a subcontractor on several clinical trials, you grab it.”
The incorporation of SCRG into bioRASI’s infrastructure is welcome as bioRASI manages “pivotal biosimilars and innovative drugs’ clinical development programs,” Reznik said.
SCRG has been operating since 2004 and has conducted numerous clinical trials for US and European sponsors in Ukraine. The company’s experience has been in Phase II and III clinical trials for indications including cardiovascular, central nervous system, oncology and infectious disease treatments, and “some of those trials resulted in drug approvals and registration by FDA and EMA,” Reznik said.
"While SCRG has been working for many global sponsors and CROs, we have never experienced the powers of project management comparable to that of bioRASI," said Dr. Veklych, SCRG's executive director. "An integrated set of tools embodied in the bioRASI Process Infrastructure (BPI) greatly enhances optimized project delivery capabilities.”